Trials / Active Not Recruiting
Active Not RecruitingNCT07104877
A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of SYH2051 in Combination With SYS6010 in Patients With Gastrointestinal Tumors Such as Advanced Colorectal Cancer
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, non-randomized trial design, including a dose escalation phase and a dose expansion phase, to evaluate the safety, tolerability and preliminary anti-tumor activity of SYS6010 in combination with SYH2051 in patients with advanced gastrointestinal tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYS6010 | Administered via intravenous infusion at the dose of 3.2-4.8 mg/kg |
| DRUG | SYH2051 | Administered via oral at the dose of 40-80 mg |
Timeline
- Start date
- 2024-04-18
- Primary completion
- 2024-11-01
- Completion
- 2026-04-30
- First posted
- 2025-08-05
- Last updated
- 2025-08-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07104877. Inclusion in this directory is not an endorsement.